One Node, Isolated Tumor Cells Only: Does KATHERINE Actually Reach This Far
The breast itself achieved a pathologic complete response. The only residual disease anywhere is isolated tumor cells in a single lymph node — a finding AJCC classifies as node-negative but KATHERINE's own eligibility criteria may or may not have been written to exclude.
Marcus T., a 58-year-old long-haul truck driver, has spent thirty years reading his own body for early warning signs the way he reads a dashboard — which is why the lump he found in the shower during a stopover in Nebraska got a same-week workup instead of the usual months of putting it off. Six cycles of neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab later, his post-surgical pathology came back with genuinely good news: no residual invasive or in situ disease anywhere in the breast, a true ypT0. The complication sits in the nodes, not the breast — one of three sentinel nodes shows isolated tumor cells, a cluster under 0.2mm, staged ypN0(i+) under AJCC criteria specifically because a finding that small does not count as node-positive disease.
KATHERINE randomized patients with residual invasive disease in the breast or axillary nodes after neoadjuvant HER2-targeted therapy to fourteen cycles of T-DM1 versus continued trastuzumab, and found a substantial three-year invasive disease-free survival benefit — 88.3% versus 77.0% — specifically in that residual-disease population. Patients who achieved a true pathologic complete response, ypT0/is with node-negative pathology, were excluded from the trial altogether, because that population's recurrence risk is already low enough that the trial was never designed to test whether escalation helps them. AJCC classifies isolated tumor cells as N0, which places Marcus, by staging convention, inside the excluded population. But KATHERINE's own protocol defined eligibility as residual invasive disease in the breast or axillary nodes — a criterion written to exclude residual in situ disease, not to adjudicate a nodal deposit measured in tenths of a millimeter. Isolated tumor cells are, definitionally, invasive tumor cells that survived six cycles of dual HER2 blockade plus chemotherapy, which the AJCC N0(i+) label does not make disappear; it reclassifies them for staging. The trial's language and the staging convention were written for different purposes and neither was drafted with Marcus in mind.
Medical oncology, reviewing the pathology report
By AJCC convention this is ypT0 ypN0 — a true pathologic complete response. KATHERINE excluded exactly this population. I would continue trastuzumab alone and not add fourteen cycles of T-DM1, with its own neuropathy and thrombocytopenia risk, to a patient who by the trial's own entry criteria doesn't belong in the escalation arm.
I want to push back on reading N0(i+) as equivalent to N0 for this specific question. AJCC built the (i+) modifier for prognostic staging and epidemiologic comparability across cancer registries — it was never built to answer "did this patient's disease survive six cycles of definitive systemic therapy," which is the actual question KATHERINE is being asked to answer here.
You're right that the staging convention exists for a different purpose than treatment selection — but conventions get borrowed for treatment decisions all the time because there's no separate framework built for every question. The honest problem isn't that AJCC is being misused; it's that KATHERINE's own published eligibility language doesn't resolve this specific edge case cleanly either way.
Both readings have real support, and I don't think this resolves into a clean answer tonight. What I can offer is what T-DM1 actually costs him if we escalate on an ambiguous indication: his neuropathy is already Grade 1 from docetaxel, and T-DM1's own peripheral neuropathy signal, while generally milder than a taxane's, adds onto an existing nerve injury rather than starting from zero — a real, patient-specific cost that the population-level DFS numbers from KATHERINE don't individually price in for him.
Not agreed at the end of the discussion, and explicitly left that way rather than forced to a vote: the pathologist and medical oncologist read the same isolated-tumor-cells finding as, respectively, real residual disease and a true complete response.
T-DM1 for 14 cycles begins this week, accepting the added neuropathy risk on top of his existing Grade 1 deficit.
Trastuzumab continues alone to complete one year, with closer interim surveillance given the genuine ambiguity in his pathology.